Trevi Therapeutics, Inc. (TRVI) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on June 3, 2025, by Trevi Therapeutics, Inc., a Delaware corporation. The filing announces the entry into a material definitive agreement for an underwritten public offering of common stock. The Company is a clinical-stage biopharmaceutical company focused on developing Haduvio for the treatment of chronic cough in various patient populations.
Key Financial Metrics and Transaction Details
- Offering Size: 17,400,000 shares of Common Stock.
- Public Offering Price: $5.75 per share.
- Underwriting Price: $5.405 per share.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 2,610,000 additional shares.
- Estimated Net Proceeds: Approximately $93.7 million (base case) or $107.8 million (if over-allotment is fully exercised), after deducting discounts, commissions, and estimated expenses.
- Closing Date: Expected on or about June 5, 2025.
- Underwriters: Morgan Stanley & Co. LLC, Leerink Partners LLC, Stifel, Nicolaus & Company, Incorporated, and Cantor Fitzgerald & Co.
Material Changes and Use of Proceeds
The primary material change is the execution of the underwriting agreement to raise capital. The Company intends to use existing cash, cash equivalents, marketable securities, and the net proceeds from this Offering to fund:
- Clinical development of Haduvio for chronic cough in patients with idiopathic pulmonary fibrosis (IPF).
- Clinical development for chronic cough in patients with non-IPF interstitial lung disease (non-IPF ILD).
- Clinical development for patients with refractory chronic cough (RCC).
- Working capital and general corporate purposes.
Guidance, Outlook, and Risks
Outlook: Management believes the combined cash resources will be sufficient to fund operating expenses and capital expenditures into 2029. This runway is projected to support two Phase 3 trials for IPF, a trial for non-IPF ILD, and a planned Phase 2b trial for RCC.
Limitations: The Company explicitly states that these resources will not be sufficient to fund Haduvio or any future product candidates through regulatory approval. Substantial additional capital will be required for commercialization.
Risks: The filing highlights uncertainties regarding market conditions, the completion of the Offering, and the accuracy of cash runway estimates. The Company notes it may need to obtain additional financing sooner than expected, which could delay trials.
Investor Verification Checklist
- Verify the final closing of the Offering and the actual net proceeds received on or after June 5, 2025.
- Confirm whether the underwriters exercise the option to purchase the 2,610,000 additional shares.
- Review the "Risk Factors" section in the preliminary prospectus supplement filed on June 2, 2025, for detailed risks.
- Monitor future filings for updates on the Company's cash burn rate and the timeline for raising additional capital post-2029.
- Check the status of the Haduvio clinical trials (Phase 3 for IPF, non-IPF ILD, and Phase 2b for RCC) in subsequent reports.